publications-banner
Information about pipeline products
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
PublicationView
Edoxaban
Periprocedural edoxaban management and clinical outcomes in patients undergoing transcatheter cardiovascular procedures in the EMIT-AF/VTE program
Dato-DXd
TROPION-Breast03: A randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy
Edoxaban
Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year data from the ETNA-AF-Europe study
T-DXd
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial
Dato-DXd
Datopotamab deruxtecan in advanced or metastatic HR+/HER2— and triple-negative breast cancer: Results from the phase I TROPION-PanTumor01 study
Other/Multi
A retrospective study of do-not-do practice recommendations in metastatic breast cancer in Spain
Edoxaban
Pharmacokinetics of edoxaban 15 mg in very elderly patients with nonvalvular atrial fibrillation: A subanalysis of the ELDERCARE-AF study
Edoxaban
Venous thromboembolism in Japanese patients with breast cancer: Subgroup analysis of the Cancer-VTE registry
Other/Multi
Real-world evidence of treatment patterns and survival of metastatic gastric cancer patients in Germany